Alnylam Pharmaceuticals (ALNY) 10-K2016 FY Annual report

Filed: 15 Feb 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Alprolix, aminotransferase, annum, aspect, assay, assemble, assembled, background, BAY, begun, bi, BMN, BOA, borrower, borrowing, breakage, breakdown, Brexit, buildup, bypassing, calcium, card, chest, CMO, collateral, cough, creatine, custody, deadline, deep, default, diagnosed, diarrhea, DMC, drawn, echocardiographic, eighteen, embolism, exit, extraordinary, Fargo, fate, fatigue, feedback, footnote, footprint, fuel, gait, gastroesophageal, givosiran, great, Greenstreet, guarantor, hasten, hATTR, headache, hepatoxicity, Highgate, hoc, hub, hypoesthesia, Idelvion, imbalance, inaccuracy, inclisiran, incremental, Indivior, infancy, insoluble, inter, interval, inventory, Jan, lactic, Lastly, leg, lender, LIBOR, loan, longest, Maidenhead, MBChB, Melinda, mode, movement, myalgia, naive, nonpayment, oxalate, Pacira, persist, phosphokinase, plant, platelet, POC, precedent, premium, prepay, pulmonary, Rachel, radiopharmaceutical, ready, referendum, refinancing, reiterated, relieve, repeal, revealed, reversible, rich, shareholder, shorter, signal, spared, sparing, Spark, speed, starve, substrate, Switzerland, Sy, technique, tetramer, transition, trough, ULN, unclear, unreliable, usage, view, worsening, Yvonne, Zug

Removed: AAT, affirmed, American, amyloid, AstraZeneca, attenuated, banc, Baxter, biomarker, BioScience, Boston, capitalize, carotid, certiorari, circulating, CoA, consisted, consortia, constituted, Contemporaneously, covenant, Cubist, daily, database, defendant, define, deposited, dissociation, dropping, dysregulated, earning, eliminating, en, erythema, exciting, existence, FAC, FDAAA, FEIBA, fibrinogen, FII, fill, FX, FXI, group, hemolytic, HMG, hyperlipidemia, hypertriglyceridemia, Idec, idiopathic, inhibition, Insider, intravenously, jurisdiction, kinase, launched, leased, leverage, mediated, mixed, modality, nadir, nanoparticle, neutralizing, nonprofit, nonrecognized, North, Obama, OOPD, petition, preexisting, prevalence, proportion, purpose, Questionnaire, refusing, rehearing, remanded, rendered, selecting, senile, separating, sequestration, serine, shelf, shortage, speaking, split, SSA, stay, stayed, Stroke, sublease, Supreme, suspending, Taxpayer, terminating, Tothe, tracking, TTRin, universe, utilization, variant, writ, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ALNY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Alnylam Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Michael P. Mason, Vice President of Finance and Treasurer of the Company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that, to his knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: February 15, 2017		/s/ Michael P. Mason
		Michael P. Mason
		Vice President of Finance and Treasurer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.